Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Altamura

Showing results (121-130 of 135) with videos related to

Pageof 14
Sort By:
Frontiers in Human Neuroscience|May 7, 2021
Pathophysiological Bases of Comorbidity in MigraineClaudia Altamura, Ilenia Corbelli, Marina de Tommaso, et al.
The Journal of Headache and Pain|November 1, 2022
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patientsPiero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
The Journal of Headache and Pain|May 4, 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
Cephalalgia : an International Journal of Headache|April 23, 2025
Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study)Fabrizio Vernieri, Luigi Francesco Iannone, Flavia Lo Castro, et al.
Journal of Neurology|June 28, 2022
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experienceClaudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.
European Journal of Neurology|November 26, 2021
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life studyFabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
BMC Cardiovascular Disorders|April 14, 2026
Ferritin and transferrin predict common carotid intima-media thickness in females: a machine-learning informed individual participant data meta-analysisAnand Ruban Agarvas, Richard Sparla, Janice L Atkins, et al.
Journal of Neurology|April 2, 2024
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Journal of Neurology|January 17, 2024
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Journal of Neurology|November 3, 2022
OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter studyClaudia Altamura, R Ornello, F Ahmed, et al.
Pageof 14

Showing results (121-130 of 135) with videos related to

Sort By:
Pageof 14
Frontiers in Human Neuroscience|May 7, 2021
Pathophysiological Bases of Comorbidity in MigraineClaudia Altamura, Ilenia Corbelli, Marina de Tommaso, et al.
The Journal of Headache and Pain|November 1, 2022
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patientsPiero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
The Journal of Headache and Pain|May 4, 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
Cephalalgia : an International Journal of Headache|April 23, 2025
Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study)Fabrizio Vernieri, Luigi Francesco Iannone, Flavia Lo Castro, et al.
Journal of Neurology|June 28, 2022
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experienceClaudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.
European Journal of Neurology|November 26, 2021
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life studyFabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
BMC Cardiovascular Disorders|April 14, 2026
Ferritin and transferrin predict common carotid intima-media thickness in females: a machine-learning informed individual participant data meta-analysisAnand Ruban Agarvas, Richard Sparla, Janice L Atkins, et al.
Journal of Neurology|April 2, 2024
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Journal of Neurology|January 17, 2024
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Journal of Neurology|November 3, 2022
OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter studyClaudia Altamura, R Ornello, F Ahmed, et al.
Pageof 14